PolyMedica
This article was originally published in The Gray Sheet
Executive Summary
Formal investigation by the Securities and Exchange Commission into "accounting matters, financial reports, other public disclosures and sales of the company's securities" is disclosed Dec. 4. The formal order of investigation expands an ongoing inquiry and enables the SEC to obtain relevant information from third parties, PolyMedica explains. The diabetes product supplier acknowledged in August that it faced a criminal investigation by the U.S. Attorney's Office for the Southern District of Florida related to alleged over-billing ("The Gray Sheet" Aug. 13, 2001, p. 14)...